{"source_content":"行业研究证券研究报告行业重大事件点评报告2月血制品行业批签发数据点评--医药行业点评报告分析师：王雯执业证书编号：S1380516110001联系电话：010-88300898邮箱：wangwen@gkzq.com.cn医药生物与上证综指走势图数据来源：wind，国开证券研究部行业评级中性相关报告1月血制品行业批签发数据点评——医药行业点评报告2021年3月22日日前，2021年2月血制品批签发数据基本公布完毕。2月，我国血制品新增批签发618.1万瓶，同比下滑48%，环比下滑12%。前2月，血制品共实现批签发1319.8万瓶，同比下滑32%。重点品种静丙、人血白蛋白、人凝血酶原复合物、人纤维蛋白原批签发量同比都有较大幅度下降人血白蛋白2月份批签发286.2万瓶，同比下滑58%。其中进口白蛋白批签发172.9万瓶（-63%），国产白蛋白批签发113.2万瓶（-47.5%）。前2月，进口白蛋白的批签发量持续降低，合计共批签发434.4万支，下降44%。我们认为进口白蛋白批签发量的走势值得重点关注。由于去年海外疫情的持续，进口白蛋白的供给偏紧有望在今年陆续传导给国内。若进口白蛋白持续供给紧张，国内白蛋白价格存有一定的上涨空间。静丙方面，2月份共批签发静丙65.95万瓶，同比下滑-67%。前2月静丙共批签发170.8万瓶，同比下滑-47%。除泰邦生物外，几大血制品上市公司静丙批签发量都有一定下降。特免方面，2月狂免、破免及乙免分别批签发169.3万瓶（+19%）、45.7万瓶（-10%）及10.1万瓶（+7%）。因子类产品方面，2月人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发12.1万瓶（+123%）、7.9万瓶（-37%）和6.3万瓶（-49%）。前2月，人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发19.1万瓶（-56%）、18.1万瓶（-8%）和11万瓶（-40%）。虽2月人凝血因子(Ⅷ)1月批签发量同比大幅提升，但前2月批签发量仍同比下滑超过50%。从上市公司看，天坛生物白蛋白批签发量前2月同比增长27%，静丙、狂免批签发量同比分别下滑11%和31%。华兰生物前2月人血白蛋白、静丙的批签发量下降较多，同比下滑-76%和-67%。双林生物前2月除静丙批签发量有个位数下滑外，其余品种批签发量均有一定增长。前2月博雅生物白蛋白批签发量和纤原批签发量分别同比增长26%和91%。上海莱士2月除狂免和破免批签发量同比增长外，其余品种均有一定程度下滑。卫光生物2月仅白蛋白、狂免和纤原实现批签发，均呈现一定程度下滑。整体看，我国血制品批签发量在今年前2月呈现较明显的下降，有春节放假及高基数等多重影响。我们认为行业需求稳定增长，在血浆资源供给偏紧及行业多年去库存背景下，供需关系演变值得重点关注，特别是今年以来进口白蛋白批签发量下滑较为明显。建议逢低关注以天坛生物、华兰生物为代表的行业龙头。风险提示：疫情影响超预期；行业监管政策进一步收紧；医保政策压力；行业事件性负面冲击；上市公司业绩增长低于预期；国内外经济形势持续恶化风险；国内外市场整体系统性风险。行业重大事件点评报告请务必阅读正文之后的免责条款部分2of5日前，中国食品药品检定研究院及各地药品检验所已陆续将2021年2月我国血制品批签发数据披露完毕（吉林省药品检验所批签发数据截至2月8日）。2021年2月，我国血制品实现批签发618.1万瓶，同比下滑48%，环比下滑12%。前2月，血制品共实现批签发1319.8万瓶，同比下滑32%。2月，重点品种静丙、人血白蛋白、人凝血酶原复合物、人纤维蛋白原批签发量同比都有较大幅度下降，预计春节假期批签发工作日的缩短是主要原因之一。另外去年受疫情影响，以静丙、人血白蛋白为代表的血制品加速批签发供给市场，因此今年在较高基数上批签发量有较大回落。分品种看，人血白蛋白2月份批签发286.2万瓶（统一折算为10g规格），同比下滑58%。其中进口白蛋白批签发172.9万瓶（-63%），国产白蛋白批签发113.2万瓶（-47.5），进口白蛋白占比60.43%，国产白蛋白占比39.57%。前2月，进口白蛋白的批签发量持续降低，合计共批签发434.4万支，下降44%。国产白蛋白共批签发285.6万瓶，同比下降17%，小于进口白蛋白批签发下降幅度。2月，仅百特、基立福和CSL三家公司实现进口批签发，且各外资公司批签发量均有较大幅度的下降。我们认为进口白蛋白批签发量的走势值得重点关注。由于去年海外疫情的持续，进口白蛋白的供给偏紧有望在今年陆续传导给国内。若进口白蛋白持续供给紧张，国内白蛋白价格存有一定的上涨空间。静丙方面，2月份共批签发静丙65.95万瓶（含冻干，统一折算为2.5g规格），同比下滑-67%。前2月静丙共批签发170.8万瓶，同比下滑-47%。除泰邦生物外，几大血制品上市公司静丙批签发量都有一定下降。特免方面，2月狂免、破免及乙免分别批签发169.3万瓶（+19%）、45.7万瓶（-10%）及10.1万瓶（+7%）。前2月，破免及乙免分别批签发210.1万瓶（-4%）、110.6万瓶（+24%）及34.6万瓶（+79%）。因子类产品方面，2月人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发12.1万瓶（+123%）、7.9万瓶（-37%）和6.3万瓶（-49%）。前2月，人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发19.1万瓶（-56%）、18.1万瓶（-8%）和11万瓶（-40%）。虽2月人凝血因子(Ⅷ)1月批签发量同比大幅提升，但前2月批签发量仍同比下滑超过50%。另外纤原和人凝血酶原复合物前2月批签发量也有较大幅度下滑，有待进一步跟踪。从上市公司看，2月天坛生物白蛋白、静丙、狂免、破免共4个产品实现批签发，其中白蛋白批签发量前2月同比增长27%，静丙、狂免批签发量同比分别下滑11%和31%，去年同期未有破免批签发。华兰生物2月白蛋白、静丙、人凝血因子(Ⅷ)、凝血酶原共4个品种实现批签发，前2月人血白蛋白、静丙的批签发量下降较多，同比下滑-76%和-67%。除乙免批签发量同比增长47%外，人凝血因子(Ⅷ)、凝血行业重大事件点评报告请务必阅读正文之后的免责条款部分3of5酶原的批签发量均有一定下滑，分别为-40%和-18%。双林生物2月仅白蛋白、静丙、狂免3个产品实现批签发。前2月公司除静丙批签发量有个位数下滑外，其余品种批签发量均有一定增长，人凝血因子(Ⅷ)为去年获批后首次批签发，人血白蛋白批签发量同比增长18%，狂免、破免批签发量也大幅增长。博雅生物2月份批签发白蛋白、静丙、纤原和凝血酶原4个品种，前2月白蛋白批签发量和纤原批签发量分别同比增长26%和91%。上海莱士2月批签发白蛋白、静丙、乙免、破免、人凝血因子(Ⅷ)和纤原6个品种，除狂免和破免批签发量同比增长外，其余品种均有一定程度下滑。卫光生物2月仅白蛋白、狂免和纤原实现批签发，均呈现一定程度下滑。泰邦生物2月批签发白蛋白、静丙、狂免和凝血酶原4个品种，除静丙外，其余品种批签发量有所下滑。表1：部分上市公司1月份血制品批签发量汇总（单位：万瓶）天坛生物华兰生物双林生物博雅生物上海莱士卫光生物泰邦生物2月1-2月2月1-2月2月1-2月2月1-2月2月1-2月2月1-2月2月1-2月人血白蛋白2791791318112620505938静丙13562681961041600722狂免223700384800404025251010乙免00014000010200000破免2136000150016280006人凝血因子(Ⅷ)00440000570000纤原00000045361200人凝血酶原复合物00490011000022增速-人血白蛋白-41%27%-80%-76%70%18%-26%26%-24%-28%-54%-62%-93%-84%增速-静丙-63%-11%-88%-67%-48%-7%-53%-52%-91%-78%-100%-100%-30%12%增速狂免-17%-31%-100%-100%139%202%-100%-100%138%19%27%-38%-59%-73%增速-乙免///47%///!/////-100%-100%增速-破免//-100%-100%-100%124%///19%//-100%-81%增速-人凝血因子(Ⅷ)/-100%20%-40%////44%-57%//-100%-100%增速-人纤维蛋白原//////57%91%-51%-31%//-100%-100%增速-人凝血酶原复合物//-59%-18%////////4%-73%数据来源：中检院，国开证券研究部整体看，我国血制品批签发量在今年前2月呈现较明显的下降，有春节放假及高基数等多重影响。我们认为行业需求稳定增长，在血浆资源供给偏紧及行业多年去库存背景下，供需关系演变值得重点关注。特别是今年以来进口白蛋白批签发量下滑较为明显，受去年海外疫情影响，今年进口白蛋白的供给预期较为紧张，若进口行业重大事件点评报告请务必阅读正文之后的免责条款部分4of5白蛋白持续供给紧张，国内白蛋白价格存有一定的上涨空间，建议逢低关注以天坛生物、华兰生物为代表的行业龙头。表2：相关重点个股估值情况（EPS单位：元/股；PE单位：倍；收盘价单位：元）证券代码证券简称EPSPEEPSPE收盘价(2020E)(2020E)(2021E)(2021E)20210319600161.SH天坛生物0.5361.490.6450.9232.59002007.SZ华兰生物0.8844.021.0536.9038.74数据来源：wind、国开证券研究部注：上述公司盈利预测来源于wind一致预期。风险提示：疫情影响超预期；行业监管政策进一步收紧；医保政策压力；行业事件性负面冲击；上市公司业绩增长低于预期；国内外经济形势持续恶化风险；国内外市场整体系统性风险。行业重大事件点评报告请务必阅读正文之后的免责条款部分5of5分析师简介承诺王雯，CFA、CPA，天津大学学士，对外经济贸易大学硕士研究生，曾任渤海证券医药行业分析师，8年行业研究经验。本人具有中国证券业协会授予的证券投资咨询执业资格并注册登记为证券分析师，保证报告所采用的数据均来自合规公开渠道，分析逻辑基于作者的专业与职业理解。本报告清晰准确地反映了作者的研究观点，力求独立、客观和公正，研究结论不受任何第三方的授意或影响，特此承诺。国开证券投资评级标准行业投资评级强于大市：相对沪深300指数涨幅10%以上；中性：相对沪深300指数涨幅介于-10%～10%之间；弱于大市：相对沪深300指数跌幅10%以上。短期股票投资评级强烈推荐：未来六个月内，相对沪深300指数涨幅20%以上；推荐：未来六个月内，相对沪深300指数涨幅介于10%～20%之间；中性：未来六个月内，相对沪深300指数涨幅介于-10%～10%之间；回避：未来六个月内，相对沪深300指数跌幅10%以上。长期股票投资评级A：未来三年内，相对于沪深300指数涨幅在20%以上；B：未来三年内，相对于沪深300指数涨跌幅在20%以内；C：未来三年内，相对于沪深300指数跌幅在20%以上。免责声明国开证券股份有限公司经中国证券监督管理委员会核准，具有证券投资咨询业务资格。本报告仅供国开证券股份有限公司（以下简称“本公司”）的客户使用。本公司不会因接收人收到本报告而视其为客户。本报告信息均来源于公开资料，本公司对这些信息的准确性和完整性不作任何保证。本报告所载的资料、意见及推测仅反映本公司于发布本报告当日的判断。在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告。报告中的内容和意见仅供参考，并不构成对所述证券买卖的出价或询价。本报告所载信息均为个人观点，并不构成所涉及证券的个人投资建议，也未考虑到个别客户特殊的投资目标、财务状况或需求。客户应考虑本报告中的任何意见或建议是否符合其特定状况。本文中提及的投资价格和价值以及这些投资带来的收入可能会波动。本公司及分析师均不会承担因使用报告而产生的任何法律责任。客户（投资者）必须自主决策并自行承担投资风险。本报告版权仅为本公司所有，本公司对本报告保留一切权利，未经书面许可，任何机构和个人不得以任何形式翻版、复制、发表或引用本报告的任何部分。如征得本公司同意进行引用、刊发的，需在允许的范围内使用，并注明出处为“国开证券”，且不得对本报告进行任何有悖原意的引用、删节和修改。国开证券研究部地址：北京市阜成门外大街29号国家开发银行8层","data":[{"id":"1","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"2月，我国血制品新增批签发618.1万瓶","content_offset":["208","228"],"indicators":[{"indicator_name":"批签发量","indicator_value":["618.1万瓶","221","228"],"indicator_element":{"时间":["2月","208","210"],"行业":["血制品","213","216"],"区域":["我国","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑48%","content_offset":["229","236"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑48%","231","236"],"indicator_element":{"时间":["2月","191","193"],"行业":["血制品","151","154"],"区域":["我国","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"环比下滑12%","content_offset":["237","244"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["下滑12%","239","244"],"indicator_element":{"时间":["2月","191","193"],"行业":["血制品","151","154"],"区域":["我国","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月，血制品共实现批签发1319.8万瓶","content_offset":["245","266"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1319.8万瓶","258","266"],"indicator_element":{"时间":["前2月","245","248"],"行业":["血制品","249","252"],"产品":["人血白蛋白","282","287"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑32%","content_offset":["267","274"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑32%","269","274"],"indicator_element":{"时间":["前2月","245","248"],"行业":["血制品","193","196"],"产品":["人血白蛋白","282","287"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"人血白蛋白2月份批签发286.2万瓶","content_offset":["317","335"],"indicators":[{"indicator_name":"批签发量","indicator_value":["286.2万瓶","328","335"],"indicator_element":{"时间":["2月","322","324"],"行业":["血制品","249","252"],"产品":["人血白蛋白","317","322"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑58%","content_offset":["336","343"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑58%","338","343"],"indicator_element":{"时间":["2月","246","248"],"行业":["血制品","249","252"],"产品":["人血白蛋白","282","287"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"其中进口白蛋白批签发172.9万瓶（-63%）","content_offset":["344","367"],"indicators":[{"indicator_name":"批签发量","indicator_value":["172.9万瓶（-63%））","-1","-1"],"indicator_element":{"时间":["2月","246","248"],"行业":["血制品","249","252"],"产品":["进口白蛋白","346","351"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"国产白蛋白批签发113.2万瓶（-47.5%）","content_offset":["368","391"],"indicators":[{"indicator_name":"批签发量","indicator_value":["113.2万瓶（-47.5%）","376","391"],"indicator_element":{"时间":["2月","322","324"],"行业":["血制品","585","588"],"产品":["国产白蛋白","368","373"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月，进口白蛋白的批签发量持续降低，合计共批签发434.4万支","content_offset":["392","424"],"indicators":[{"indicator_name":"批签发量","indicator_value":["434.4万支","417","424"],"indicator_element":{"时间":["前2月","392","395"],"行业":["血制品","585","588"],"产品":["进口白蛋白","396","401"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"下降44%","content_offset":["425","430"],"indicators":[{"indicator_name":"批签发量","indicator_value":["下降44%","425","430"],"indicator_element":{"时间":["前2月","392","395"],"行业":["血制品","585","588"],"产品":["进口白蛋白","346","351"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"2月份共批签发静丙65.95万瓶","content_offset":["524","540"],"indicators":[{"indicator_name":"批签发量","indicator_value":["65.95万瓶","533","540"],"indicator_element":{"时间":["2月","524","526"],"行业":["血制品","585","588"],"产品":["静丙","531","533"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑-67%","content_offset":["541","549"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑-67%","543","549"],"indicator_element":{"时间":["2月","524","526"],"行业":["血制品","585","588"],"产品":["静丙","519","521"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月静丙共批签发170.8万瓶","content_offset":["550","566"],"indicators":[{"indicator_name":"批签发量","indicator_value":["170.8万瓶","559","566"],"indicator_element":{"时间":["前2月","550","553"],"行业":["血制品","585","588"],"产品":["静丙","553","555"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑-47%","content_offset":["567","575"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑-47%","569","575"],"indicator_element":{"时间":["前2月","550","553"],"行业":["血制品","585","588"],"产品":["静丙","519","521"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"2月狂免、破免及乙免分别批签发169.3万瓶（+19%）、45.7万瓶（-10%）及10.1万瓶（+7%）","content_offset":["610","663"],"indicators":[{"indicator_name":"批签发量","indicator_value":["169.3万瓶（+19%）","625","638"],"indicator_element":{"产品":["狂免","612","614"],"时间":["2月","610","612"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["45.7万瓶（-10%）","639","651"],"indicator_element":{"产品":["破免","615","617"],"时间":["2月","610","612"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["10.1万瓶（+7%）","652","663"],"indicator_element":{"产品":["乙免","618","620"],"时间":["2月","610","612"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"2月人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发12.1万瓶（+123%）、7.9万瓶（-37%）和6.3万瓶（-49%））","content_offset":["-1","-1"],"indicators":[{"indicator_name":"批签发量","indicator_value":["12.1万瓶（+123%）","26","39"],"indicator_element":{"产品":["人凝血因子(Ⅷ)","1","9"],"时间":["2月","-1","1"],"行业":["血制品","22","25"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["7.9万瓶（-37%）","40","51"],"indicator_element":{"产品":["纤原","10","12"],"时间":["2月","-1","1"],"行业":["血制品","22","25"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["6.3万瓶（-49%））","52","64"],"indicator_element":{"产品":["人凝血酶原复合物","13","21"],"时间":["2月","-1","1"],"行业":["血制品","22","25"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月，人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发19.1万瓶（-56%）、18.1万瓶（-8%）和11万瓶（-40%）","content_offset":["737","801"],"indicators":[{"indicator_name":"批签发量","indicator_value":["19.1万瓶（-56%）","766","778"],"indicator_element":{"产品":["人凝血因子(Ⅷ)","741","749"],"时间":["前2月","737","740"],"行业":["血制品","1081","1084"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["18.1万瓶（-8%）","779","790"],"indicator_element":{"产品":["纤原","750","752"],"时间":["前2月","737","740"],"行业":["血制品","1081","1084"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["11万瓶（-40%）","791","801"],"indicator_element":{"产品":["人凝血酶原复合物","753","761"],"时间":["前2月","737","740"],"行业":["血制品","1081","1084"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"但前2月批签发量仍同比下滑超过50%","content_offset":["826","844"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑超过50%","837","844"],"indicator_element":{"时间":["前2月","827","830"],"行业":["血制品","1081","1084"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"2021年2月，我国血制品实现批签发618.1万瓶","content_offset":["1394","1419"],"indicators":[{"indicator_name":"批签发量","indicator_value":["618.1万瓶","1412","1419"],"indicator_element":{"时间":["2021年2月","1394","1401"],"行业":["血制品","1404","1407"],"区域":["我国","1402","1404"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑48%","content_offset":["229","236"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑48%","231","236"],"indicator_element":{"时间":["2月","191","193"],"行业":["血制品","151","154"],"区域":["我国","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"环比下滑12%","content_offset":["237","244"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["下滑12%","239","244"],"indicator_element":{"时间":["2月","191","193"],"行业":["血制品","151","154"],"区域":["我国","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月，血制品共实现批签发1319.8万瓶","content_offset":["245","266"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1319.8万瓶","258","266"],"indicator_element":{"时间":["前2月","245","248"],"行业":["血制品","249","252"],"区域":["我国","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑32%","content_offset":["267","274"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑32%","269","274"],"indicator_element":{"时间":["前2月","245","248"],"行业":["血制品","193","196"],"区域":["我国","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"人血白蛋白2月份批签发286.2万瓶（统一折算为10g规格）","content_offset":["1596","1626"],"indicators":[{"indicator_name":"批签发量","indicator_value":["286.2万瓶","1607","1614"],"indicator_element":{"时间":["2月","1601","1603"],"行业":["血制品","1558","1561"],"产品":["人血白蛋白","1596","1601"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑58%","content_offset":["336","343"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑58%","338","343"],"indicator_element":{"时间":["2月","246","248"],"行业":["血制品","249","252"],"产品":["人血白蛋白","282","287"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"其中进口白蛋白批签发172.9万瓶（-63%）","content_offset":["344","367"],"indicators":[{"indicator_name":"批签发量","indicator_value":["172.9万瓶（-63%））","-1","-1"],"indicator_element":{"时间":["2月","246","248"],"行业":["血制品","249","252"],"产品":["进口白蛋白","346","351"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"国产白蛋白批签发113.2万瓶（-47.5）","content_offset":["1659","1681"],"indicators":[{"indicator_name":"批签发量","indicator_value":["113.2万瓶（-47.5）","1667","1681"],"indicator_element":{"时间":["2月","1601","1603"],"行业":["血制品","2006","2009"],"产品":["国产白蛋白","1659","1664"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"进口白蛋白占比60.43%","content_offset":["1682","1695"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["60.43%","1689","1695"],"indicator_element":{"时间":["2月","1601","1603"],"行业":["血制品","2006","2009"],"产品":["进口白蛋白","1682","1687"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"国产白蛋白占比39.57%","content_offset":["1696","1709"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["39.57%","1703","1709"],"indicator_element":{"时间":["2月","1601","1603"],"行业":["血制品","2006","2009"],"产品":["国产白蛋白","1696","1701"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月，进口白蛋白的批签发量持续降低，合计共批签发434.4万支","content_offset":["392","424"],"indicators":[{"indicator_name":"批签发量","indicator_value":["434.4万支","417","424"],"indicator_element":{"时间":["前2月","392","395"],"行业":["血制品","585","588"],"产品":["进口白蛋白","396","401"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"下降44%","content_offset":["425","430"],"indicators":[{"indicator_name":"批签发量","indicator_value":["下降44%","425","430"],"indicator_element":{"时间":["前2月","392","395"],"行业":["血制品","585","588"],"产品":["进口白蛋白","346","351"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"国产白蛋白共批签发285.6万瓶","content_offset":["1749","1765"],"indicators":[{"indicator_name":"批签发量","indicator_value":["285.6万瓶","1758","1765"],"indicator_element":{"时间":["前2月","1710","1713"],"行业":["血制品","2006","2009"],"产品":["国产白蛋白","1749","1754"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下降17%","content_offset":["1766","1773"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降17%","1768","1773"],"indicator_element":{"时间":["前2月","1710","1713"],"行业":["血制品","2006","2009"],"产品":["国产白蛋白","1696","1701"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"2月份共批签发静丙65.95万瓶（含冻干，统一折算为2.5g规格）","content_offset":["1928","1961"],"indicators":[{"indicator_name":"批签发量","indicator_value":["65.95万瓶","1937","1944"],"indicator_element":{"时间":["2月","1928","1930"],"行业":["血制品","2006","2009"],"产品":["静丙","1935","1937"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑-67%","content_offset":["541","549"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑-67%","543","549"],"indicator_element":{"时间":["2月","524","526"],"行业":["血制品","585","588"],"产品":["静丙","519","521"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月静丙共批签发170.8万瓶","content_offset":["550","566"],"indicators":[{"indicator_name":"批签发量","indicator_value":["170.8万瓶","559","566"],"indicator_element":{"时间":["前2月","550","553"],"行业":["血制品","585","588"],"产品":["静丙","553","555"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"同比下滑-47%","content_offset":["567","575"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑-47%","569","575"],"indicator_element":{"时间":["前2月","550","553"],"行业":["血制品","585","588"],"产品":["静丙","519","521"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"2月狂免、破免及乙免分别批签发169.3万瓶（+19%）、45.7万瓶（-10%）及10.1万瓶（+7%）","content_offset":["610","663"],"indicators":[{"indicator_name":"批签发量","indicator_value":["169.3万瓶（+19%）","625","638"],"indicator_element":{"产品":["狂免","612","614"],"时间":["2月","610","612"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["45.7万瓶（-10%）","639","651"],"indicator_element":{"产品":["破免","615","617"],"时间":["2月","610","612"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["10.1万瓶（+7%）","652","663"],"indicator_element":{"产品":["乙免","618","620"],"时间":["2月","610","612"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月，破免及乙免分别批签发210.1万瓶（-4%）、110.6万瓶（+24%）及34.6万瓶（+79%）","content_offset":["2085","2138"],"indicators":[{"indicator_name":"批签发量","indicator_value":["210.1万瓶（-4%）","2099","2111"],"indicator_element":{"产品":["破免","2089","2091"],"时间":["前2月","2085","2088"],"行业":["血制品","2006","2009"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["110.6万瓶（+24%）","2112","2125"],"indicator_element":{"产品":["乙免","2092","2094"],"时间":["前2月","2085","2088"],"行业":["血制品","2006","2009"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["34.6万瓶（+79%）","2126","2138"],"indicator_element":{"产品":["乙免","2092","2094"],"时间":["前2月","2085","2088"],"行业":["血制品","2006","2009"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"2月人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发12.1万瓶（+123%）、7.9万瓶（-37%）和6.3万瓶（-49%）","content_offset":["672","736"],"indicators":[{"indicator_name":"批签发量","indicator_value":["12.1万瓶（+123%）","699","712"],"indicator_element":{"产品":["人凝血因子(Ⅷ)","674","682"],"时间":["2月","672","674"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["7.9万瓶（-37%）","713","724"],"indicator_element":{"产品":["纤原","683","685"],"时间":["2月","672","674"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["6.3万瓶（-49%）","725","736"],"indicator_element":{"产品":["人凝血酶原复合物","686","694"],"时间":["2月","672","674"],"行业":["血制品","585","588"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"前2月，人凝血因子(Ⅷ)、纤原及人凝血酶原复合物分别批签发19.1万瓶（-56%）、18.1万瓶（-8%）和11万瓶（-40%）","content_offset":["737","801"],"indicators":[{"indicator_name":"批签发量","indicator_value":["19.1万瓶（-56%）","766","778"],"indicator_element":{"产品":["人凝血因子(Ⅷ)","741","749"],"时间":["前2月","737","740"],"行业":["血制品","1081","1084"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["18.1万瓶（-8%）","779","790"],"indicator_element":{"产品":["纤原","750","752"],"时间":["前2月","737","740"],"行业":["血制品","1081","1084"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["11万瓶（-40%）","791","801"],"indicator_element":{"产品":["人凝血酶原复合物","753","761"],"时间":["前2月","737","740"],"行业":["血制品","1081","1084"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"医药行业点评报告：2月血制品行业批签发数据点评.pdf","content":"虽2月人凝血因子(Ⅷ)1月批签发量同比大幅提升，但前2月批签发量仍同比下滑超过50%","content_offset":["802","844"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑超过50%","837","844"],"indicator_element":{"时间":["前2月","827","830"],"行业":["血制品","1081","1084"]},"indicator_supplement":{"属性":""}}]}]}